Solventum Corp (SOLV)

Solventum Corporation is a global healthcare company that develops, manufactures, and commercializes a broad portfolio of solutions leveraging material science, data science, and digital capabilities to address customer and patient needs across the healthcare continuum, from prevention through diagnosis, treatment, and recovery. With over 70 years of innovation history, the company serves a diverse customer base ranging from multidisciplinary hospitals to local clinics and practices, maintaining a global commercial footprint with sales in over 90 countries through direct-to-customer, distribution, key account management, inside sales, and e-commerce channels. Solventum operates through three reportable business segments: MedSurg (57.9% of 2025 sales), which provides negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies designed to accelerate healing and reduce total cost of care; Dental Solutions (16.2% of 2025 sales), offering a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents spanning preventative care, restoration, and orthodontics; and Health Information Systems (16.3% of 2025 sales), which provides healthcare software solutions such as computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms designed to reduce administrative burden and support value-based care.

The company's principal competitors include Smith & Nephew, Mölnlycke, Coloplast, and Convatec in advanced wound care; Becton Dickinson, ICU Medical, Medline, Cardinal Health, and Steris in infection prevention and surgical supplies; Dentsply Sirona, Envista, Straumann, Ivoclar, and Align Technology in dental and orthodontics; and Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar, and Athena in healthcare information technology. In 2025, Solventum acquired Acera Surgical, a privately held bioscience company, and divested its Purification and Filtration business to Thermo Fisher Scientific. The company employs approximately 20,000 people globally, including about 10,000 in the United States and 2,000 in Germany, with an R&D team of roughly 2,000 employees focused on developing clinically differentiated solutions across its segments.

Solventum's products are purchased principally by hospitals, physicians, and other healthcare providers who bill government programs like Medicare and Medicaid and private insurers, and the company maintains a global supply chain and distribution network, including transition agreements with 3M for manufacturing and distribution support as it continues to build independent operational capabilities following its separation from 3M.